Supporting Information

for

Self-assembling Nanoplatform Co-delivery of Brusatol to Sensitize Sorafenib for Hepatocellular Carcinoma Treatment

Fengrui Liu^{a,b†}, Senlin Li^{a†}, Chengcheng Huang^{a†}, Zhenfei Bi^a, Xiao Xiang^a , Shuqi

Zhang^a, Ruihao Yang^{a*}, Lu Zheng^{a*}

^aDepartment of Hepatobiliary Surgery, the Second Affiliated Hospital of Army Medical

University, Chongqing 400038, P. R. China

^bKey Laboratory of Tongliang District People's Hospital, Chongqing 402560, P. R. China

*: Corresponding authors: *yangruihao@alumni.sjtu.edu.cn* (R. Yang);

zhenglu@tmmu.edu.cn (L. Zheng)

[†]: These authors contributed equally to this work.

Fengrui Liu Ifrtlqrmhospital@163.com

Senlin Li lisenlin@tmmu.edu.cn

Chengcheng Huang 13883278155@163.com

Shuqi Zhang a15923676293@163.com




Figure S1 Characterizations of Bru NP and Sor NP.




Figure S2 The changes in particle size of B/S NP, B NP and S NP over a period of seven days.




Figure S3 Comparison of therapeutic effects between B/S NP and free B/S.






Figure S4 Immunofluorescence imaging exhibited nrf2 expression level in tumor-bearing mice treated with PBS, Bru NP, Sor NP, or B/S NP, respectively.